Neovacs S.A. (EPA:ALNEV)

Chuy's Holdings Statistics

Total Valuation

Neovacs has a market cap or net worth of EUR 471,859. The enterprise value is 266,778.

Market Cap	471,859
Enterprise Value	266,778

Important Dates

The next estimated earnings date is Thursday, September 4, 2025.

Earnings Date	Sep 4, 2025
Ex-Dividend Date	n/a

Share Statistics

Neovacs has 476,625 shares outstanding.

Current Share Class	476,625
Shares Outstanding	476,625
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.09
PB Ratio	0.03
P/TBV Ratio	0.03
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-0.01
EV / Sales	0.61
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.07

Financial Position

The company has a current ratio of 0.64, with a Debt / Equity ratio of 0.01.

Current Ratio	0.64
Quick Ratio	0.62
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.06
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -98.39% and return on invested capital (ROIC) is -12.21%.

Return on Equity (ROE)	-98.39%
Return on Assets (ROA)	-11.09%
Return on Invested Capital (ROIC)	-12.21%
Return on Capital Employed (ROCE)	-36.33%
Revenue Per Employee	21,697
Profits Per Employee	-1.65M
Employee Count	20
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	-1.03M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -100.00% in the last 52 weeks. The beta is -56.91, so Neovacs's price volatility has been lower than the market average.

Beta (5Y)	-56.91
52-Week Price Change	-100.00%
50-Day Moving Average	1.92
200-Day Moving Average	684.96
Relative Strength Index (RSI)	31.80
Average Volume (20 Days)	2,736,101

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Neovacs had revenue of EUR 433,937 and -32.91 million in losses.

Revenue	433,937
Gross Profit	-2.77M
Operating Income	-6.62M
Pretax Income	-33.95M
Net Income	-32.91M
EBITDA	-6.43M
EBIT	-6.62M
Earnings Per Share (EPS)	n/a

Balance Sheet

The company has 435,449 in cash and 230,367 in debt, giving a net cash position of 205,082 or 0.43 per share.

Cash & Cash Equivalents	435,449
Total Debt	230,367
Net Cash	205,082
Net Cash Per Share	0.43
Equity (Book Value)	18.06M
Book Value Per Share	n/a
Working Capital	-1.37M

Cash Flow

In the last 12 months, operating cash flow was -3.60 million and capital expenditures -79,706, giving a free cash flow of -3.68 million.

Operating Cash Flow	-3.60M
Capital Expenditures	-79,706
Free Cash Flow	-3.68M
FCF Per Share	-7.72

Margins

Gross Margin	n/a
Operating Margin	-1,525.96%
Pretax Margin	-7,823.36%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Neovacs does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-6,975.48%
FCF Yield	-780.09%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 18, 2025. It was a reverse split with a ratio of 0.001.

Last Split Date	Jul 18, 2025
Split Type	Reverse
Split Ratio	0.001

Scores

Neovacs has an Altman Z-Score of -4.83 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.83
Piotroski F-Score	3